埃索美拉唑与奥美拉唑治疗幽门螺杆菌阳性慢性胃炎的疗效比较

The efficacy comparison of esomeprazole and omeprazole to treat with the patients helicobacter pylori(Hp) positive chronic gastritis

目的比较埃索美拉唑与奥美拉唑治疗幽门螺杆菌阳性慢性胃炎的临床疗效。方法我院自2009年2月～2011年2月共收治慢性胃炎患者66例,随机分为对照组和观察组,每组33例。对照组给予奥美拉唑、阿莫西林和克拉霉素,观察组给予埃索美拉唑、阿莫西林和克拉霉素,观察两组患者的临床疗效、Hp根除率、腹痛缓解情况及不良反应。结果观察组患者的治疗总有效率96.97%、Hp根除率93.94%均高于对照组的90.91%、90.91%,不良反应发生率6.06%低于对照组的12.12%,但两组比较差异均无统计学意义(P>0.05)。观察组腹痛消失率75.76%显著高于对照组的30.30%(P<0.05)。结论埃索美拉唑与奥美拉唑治疗Hp阳性慢性胃炎的临床疗效基本相当,但埃索美拉唑的起效更迅速,对临床症状的缓解更显著,是治疗Hp阳性慢性胃炎的首选药物。

OBJECTIVE Compared the clinical efficacy of esomeprazole and omeprazole to treat the patients with Helicobacter pylori （Hp） positive chronic gastritis.METHODS 66 patients with chronic gastritis from February 2009 February 2011 in our hospital were randomly divided into control group and observation group, and each group had 33 cases. The control group was given omeprazole, amoxicillin and clarithromycin while the obser vation group was given esomeprazole, amoxicillin and clarithromycin. The clinical efficacy, Hp eradication rate, ab- dominal pain erasing and adverse reactions were compared between the two groups. RESULTS The total effective rate and the Hp eradication rate in the observation group were 96.97% and 93.94 % higher than 90.91% and 90.91% of the control group, the adverse reaction rate was 6.06 % lower than 12.12 % of the control group, however, there were no statistically significance differences between the two groups （ P 〉 0.05） ; the abdominal pain easing rate was 75.76 % higher than 30.30 % of the control group （P 〈 0.05）. CONCLUSION The clinical efficacy of esomeprazole and omeprazole for treating with Hp positive chronic gastritis is roughly equal; however, the onset of esomeprazole is more rapid and obvious than esomeprazole, and it is a good choice to treat with Hp positive chronic gastritis.